Decreased nuclear expression of FTO in human primary hepatocellular carcinoma is associated with poor prognosis.
Decreased nuclear expression of FTO in human primary hepatocellular carcinoma is associated with poor prognosis.
复制标题
DOI：
--
复制
发表时间：
2019-09
影响因子：
1.4
通讯作者：
Yue Zhao;Song You;Ya-qi Yu;S. Zhang;Pengtao Li;Y. Ye;Wen‐xiu Zhao;Jie Li;Qiu‐Shi Li;
中科院分区：
文献类型：
--
作者：
Yue Zhao;Song You;Ya-qi Yu;S. Zhang;Pengtao Li;Y. Ye;Wen‐xiu Zhao;Jie Li;Qiu‐Shi Li;
脂肪质量和肥胖相关蛋白(FTO)在脂肪质量、脂肪生成和体重的调节中起着关键作用。近年来，越来越多的研究表明FTO与各种类型的癌症有很强的相关性。然而，它在人类肝细胞癌中的作用尚不清楚。本研究旨在探讨FTO在肝细胞癌中的表达规律及临床意义。我们发现，在肝细胞癌组织中，FTO基因的表达水平显著降低。免疫组织化学分析显示，在肝细胞癌中，FTO在细胞核中的表达降低，且与甲胎蛋白水平(P<；0.001)、肿瘤大小(P<；0.001)、有无转移(P=0.025)和血管侵犯(P<；0.001)有关。FTO低表达患者的总生存期和无瘤生存期明显短于FTO正常患者(P=0.004和P=0.006)。Cox比例风险回归模型显示，FTO表达降低是影响肝癌患者预后的危险因素(P=0.022)。这些结果表明，FTO表达降低与临床病理因素相关，提示FTO可能是预测肝细胞癌患者预后不良的重要指标，可作为一种新的肝细胞癌生物标志物。
Fat mass and obesity-associated protein (FTO) has been well known for a pivotal role in regulation of fat mass, adipogenesis and body weight. In recent years, increasing studies revealed a strong association between FTO and various types of cancer. Its role in human hepatocellular carcinoma, however, remains unclear. We aimed at investigating the expression pattern and clinical significance of FTO in hepatocellular carcinoma. We found that FTO mRNA levels were significantly lower in hepatocellular carcinoma tissues. Immunohistochemical analysis showed the expression of FTO was reduced in the nuclei in hepatocellular carcinoma, and was associated with AFP level (P < 0.001), tumor size (P < 0.001), metastasis (P = 0.025) and vascular invasion (P < 0.001). Patients with decreased FTO expression had a shorter overall and tumor-free survival time (P = 0.004 and P = 0.006) than those with normal FTO expression. Cox's proportional hazard regression model revealed that reduced expression of FTO was a risk factor associated with the prognosis of HCC patients (P = 0.022). These results indicated that decreased FTO expression is correlated with clinicopathological factors, implying that FTO could be a vital predictor of poor outcome in HCC patients and serves as a novel biomarker for HCC.